| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Jasper Therapeutics, Inc.$0.58
0 (-0.33%)
D 28Pipeline Score Richly Valued Biotech · Clinical
Market Cap
25.28 M
EPS
-3.23
P/E Ratio
-
Value Trade
899.09 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
5.81 M
Operating CF
-14.55 M
Total Assets
21.18 M
Total Liabilities
17.78 M
Equity
3.40 M
D/E Ratio
12,345
-1.43 %
Week
-8.03 %
1 Month
-35.04 %
3 Month
-46.88 %
6 Month
-99.09 %
5 Year
-99.08 %
All Time
Cash Data
Cash Position
14.14 M
Monthly Burn
4.85 M
Runway
1 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.46 M
52 Week Range
0.62 - 7.19
% held by Insiders
10.03 %
% held by Institutions
47.62 %
Enterprise Value
11.89 M
Total Shares
28.00 M
Short %
7.49 %
Float Shares
22.74 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jasper Therapeutics, Inc.
277Total events
1Upcoming
51Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 1
Event history 276
Jun 1, 2026
◆Pipeline PrioritizationCorporate
Board initiates comprehensive review of strategic alternatives to maximize shareholder value
Jun 2026
◆Trial InitiationBriquilimabTrial
Phase 2b CSU study planned to commence mid-2026
chronic spontaneous urticariasource ↗
May 14, 2026
●FDA Filing AcceptedBriquilimabRegulatory Filing
Refiled updated Phase 2b protocol with FDA
chronic spontaneous urticaria (CSU)source ↗
Q2 2026
◆Trial InitiationBriquilimabTrial
Phase 2b CSU study commencement expected in mid-2026
chronic spontaneous urticariasource ↗
Mar 30, 2026
▲Full ResultsBriquilimabClinical Data
Positive preliminary data from ETESIAN study: reductions in airway hyperresponsiveness and suppressed eosinophilic response
asthmasource ↗
Mar 2, 2026
◆Oral PresentationPresentation
Jasper Therapeutics to present at 46th Annual TD Cowen Healthcare Conference
Jan 8, 2026
▲Full ResultsBriquilimabClinical Data
Updated data from open label extension: 75% complete response or well controlled disease at 12 weeks
chronic spontaneous urticariasource ↗
Jan 8, 2026
◆Oral PresentationBriquilimabPresentation
Investor webinar to present updated data from open-label extension study in CIndU
CIndUsource ↗
Drug Pipeline Intelligence
D28
Pipeline Score $4M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 30%
Micro Cap (rank 639 of 912)
Percentile RankJasper Therapeutics, Inc. faces pipeline headwinds (28/100), with $699M risk-adjusted pipeline value, led by Briquilimab in Urticaria Chronic (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Briquilimab Small molecule | Urticaria Chronic | Phase 2 | NCT06736262 | 55% | $395M | ACTIVE NOT_RECRUITING | 67 | AVERAGE | D (26) | Sep 30, 2026 | HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
briquilimab OrphanRare Pediatric | chronic spontaneous urticaria, chronic inducible urticaria, asthma | — | 2026-02-25 | positive clinical outcomes in CSU, CIndU and allergic asthma | Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference Read More | |
briquilimab OrphanRare Pediatric | chronic spontaneous urticaria, chronic inducible urticaria, asthma | — | 2026-02-25 | positive clinical outcomes in CSU, CIndU and allergic asthma | Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference Read More | |
briquilimab OrphanRare Pediatric | chronic spontaneous urticaria, chronic inducible urticaria, asthma | — | 2026-02-25 | positive clinical outcomes in CSU, CIndU and allergic asthma | Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in JSPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
JSPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
JSPR▼ -35.6%on this news
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Jasper Therapeutics is undergoing a strategic review to explore alternatives for maximizing shareholder value. This includes potential asset sales, collaborations, or a merger. The company will also implement cost-saving measures while ensuring compliance with regulatory requirements. However, there is no set timeline for this process, and outcomes remain uncertain.
Read more →JSPRJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q1 2026, highlighting advancements in the briquilimab development program for chronic spontaneous urticaria (CSU). The company refiled its Phase 2b protocol with the FDA and reported positive clinical outcomes, with a significant percentage of patients achieving a complete response. Despite a net loss of $1.2 million, Jasper aims to commence the Phase 2b study in the second half of the year.
Read more →JSPR▼ -14.3%on this news· ran to -34% by day 3
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q4 and year-end 2025, highlighting the promising data for briquilimab in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company is preparing to initiate a Phase 2b/3 study in CSU, with patient enrollment expected in the second half of 2026. Additionally, preliminary data from the ETESIAN study in asthma showed positive outcomes, although future developments will depend on strategic partnerships and available capital.
Read more →JSPRJasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Jasper Therapeutics will present at the 46th Annual TD Cowen Healthcare Conference from March 2-4, 2026. The company focuses on briquilimab, an antibody therapy for mast cell driven diseases like chronic spontaneous urticaria and asthma. The presentation will include a fireside chat on March 2, 2026, at 3:50 PM EST.
Read more →JSPR▼ -19%on this news
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria 67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a me
Jasper Therapeutics reported positive updated data from clinical studies of briquilimab for chronic spontaneous urticaria (CSU). In the BEACON study, 67% of enrolled patients achieved a complete response after 12 weeks. Similarly, the open-label extension study showed that 75% of CSU participants achieved control of their disease. The favorable safety profile and low incidence of adverse events support further development of briquilimab.
Read more →JSPR▲ +7.9%on this news· ran to -22% by day 3shared move
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8 th at 8:00am ET to p
Jasper Therapeutics has appointed Jeet Mahal as its new CEO, succeeding Ronald Martell, who led the company through significant transitions since his appointment in 2022. Mahal brings over thirty years of experience in the life sciences industry, including pivotal roles at Jasper. The company is set to commence its registrational program for its lead therapeutic, briquilimab, aimed at treating mast cell-driven diseases, including chronic spontaneous urticaria (CSU). An investor webinar is scheduled for January 8, 2026, to present updated data from the BEACON study related to CSU.
Read more →JSPR▼ -8.1%on this news
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Jasper Therapeutics reported positive preliminary data from the ETESIAN Phase 1b study of briquilimab, showing significant reductions in airway hyperresponsiveness and eosinophils in asthma patients. The drug demonstrated a favorable safety profile. Additionally, Jasper concluded its internal investigation into the BEACON study, attributing unexpected results to patient selection issues rather than drug efficacy.
Read more →JSPR▼ -8.1%on this news
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
Jasper Therapeutics will host an investor webinar on December 2nd to present preliminary findings from the ETESIAN study in asthma and discuss the BEACON study results. The event will feature remarks from company management and Dr. Martin Metz, a leading investigator. A Q&A session will follow the presentation.
Read more →JSPRJasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
Jasper Therapeutics, Inc. is involved in a class action lawsuit initiated by the DJS Law Group, claiming violations of securities laws. The lawsuit alleges that the company made misleading statements regarding its operational integrity and third-party manufacturing compliance. These claims suggest that the company's clinical trials may be adversely affected due to these discrepancies. Shareholders who purchased shares between November 30, 2023, and July 3, 2025, are encouraged to participate in recovery processes.
Read more →JSPRJasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q3 2025 and provided updates on briquilimab, an antibody therapy targeting mast cell diseases. The company is investigating efficacy results from the BEACON study and plans to report data from ongoing studies in the coming months. The CEO expressed optimism about briquilimab's potential in treating chronic urticaria and asthma.
Read more →JSPR▼ -13.8%on this newsshared move
Jasper Therapeutics to Present at Upcoming Investor Conferences
Jasper Therapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences, including the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference. The company is focused on briquilimab, a monoclonal antibody targeting mast cell diseases. Briquilimab has shown positive clinical outcomes in treating chronic spontaneous urticaria and chronic inducible urticaria.
Read more →JSPR▼ -7.9%on this news· ran to -21% by day 1shared move
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Jasper Stockholders of the November 18th Deadline for Filed Class Action
A class action lawsuit has been filed against Jasper Therapeutics, Inc. (NASDAQ:JSPR) in a California federal court, representing investors who purchased its securities from November 30, 2023 to July 3, 2025. The complaint alleges that the company made false and misleading statements about its operations and compliance, specifically regarding the reliability of its third-party manufacturers. Investors have until November 18, 2025, to apply to be lead plaintiffs in the case. The allegations outline serious concerns that could impact the clinical prospects of Jasper's products and the financial integrity of the company.
Read more →JSPRJASPER CLASS ACTION: Bragar Eagel & Squire, P.C. Reminds Jasper Stockholders of the November 18th Deadline for Filed Class Action Lawsuit
A class action lawsuit has been filed against Jasper Therapeutics, Inc. (NASDAQ: JSPR) by the law firm Bragar Eagel & Squire, P.C., on behalf of investors who acquired securities between November 30, 2023, and July 3, 2025. The lawsuit claims the company made false and misleading statements about its operations and compliance, particularly regarding third-party manufacturing practices and the clinical prospects of its product briquilimab. Investors have until November 18, 2025, to apply as lead plaintiffs.
Read more →JSPRJASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Jasper Therapeutics Stockholders to Contact the Firm Regarding Filed Class Action
A class action lawsuit has been initiated against Jasper Therapeutics, Inc. for allegedly misleading investors about its business and operational practices. The lawsuit pertains to securities purchased between November 30, 2023, and July 3, 2025, and claims that the company failed to ensure compliance with critical manufacturing regulations. The allegations suggest this non-compliance may affect the outcomes of clinical studies, therefore inflating the perceived value of the company's prospects. Investors have until November 18, 2025, to apply as lead plaintiffs.
Read more →JSPRJASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Jasper Therapeutics Investors to Contact the Firm Regarding Class Action Lawsuit
A class action lawsuit has been initiated against Jasper Therapeutics, Inc. by the law firm Bragar Eagel & Squire on behalf of investors. The lawsuit alleges that the company made materially false and misleading statements regarding its business operations and compliance policies from November 30, 2023, to July 3, 2025. Specific concerns include failures in ensuring third-party manufacturers were compliant with necessary regulations, which may compromise clinical trial outcomes and financial projections. Investors are encouraged to contact the firm for more information and to discuss potential claims.
Read more →JSPRJASPER LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Jasper Investors to Contact the Firm Regarding Class Action Lawsuit
A class action lawsuit has been initiated against Jasper Therapeutics, Inc. by Bragar Eagel & Squire, P.C. The lawsuit concerns allegations of materially false and misleading statements by the company regarding its business practices and manufacturing compliance. The allegations suggest that Jasper lacked proper controls over third-party manufacturers, potentially affecting the outcomes of clinical trials. Investors impacted during the defined class period are encouraged to contact the law firm for representation.
Read more →JSPRJASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
Jasper Therapeutics, Inc. is currently facing a class action lawsuit filed in the Northern District of California. The lawsuit alleges that Jasper made false statements regarding its business operations and compliance policies during the class period from November 30, 2023, to July 3, 2025. Key allegations include the company's failure to ensure that third-party manufacturers complied with regulations, which may negatively affect clinical trial results and the commercialization of its products. Affected investors have until November 18, 2025, to apply as lead plaintiffs.
Read more →JSPR▼ -5.5%on this news
JASPER ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Jasper Therapeutics, Inc. for alleged misleading statements regarding its business conditions and regulatory compliance. The complaint claims that the Company lacked adequate controls over third-party manufacturers, potentially jeopardizing clinical trial results and overstating financial projections. Investors affected between November 30, 2023, and July 3, 2025, are encouraged to join the lawsuit and discuss their rights with legal representatives. The deadline for investors to seek lead plaintiff status is November 18, 2025.
Read more →JSPRJasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
Jasper Therapeutics has announced the pricing of a public offering, aiming to raise approximately $30 million. The offering consists of common stock and warrants, which will be used to advance the development of briquilimab, a therapy for mast cell-driven diseases. The offering is expected to close on September 22, 2025, subject to customary conditions.
Read more →JSPRJasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
Jasper Therapeutics announced a proposed public offering of common stock and warrants to fund the development of briquilimab, a treatment for mast cell-driven diseases. The offering is subject to market conditions, and the company intends to use the proceeds for clinical advancements and general corporate purposes. TD Cowen will manage the offering, which is registered with the SEC.
Read more →JSPRJasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q2 2025, highlighting positive developments for its investigational therapy briquilimab. Significant response rates were noted across various patient cohorts, particularly in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). However, the company is currently investigating some cohorts that did not meet anticipated performance metrics. Future clinical outcomes and financial health depend on ongoing trials and market conditions, presenting both potential and risk.
Read more →JSPR▲ +21.9%on this news
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Jasper Therapeutics has announced a corporate reorganization aimed at extending its cash runway, which includes a significant workforce reduction of about 50%. The company will focus its resources on the development of briquilimab for chronic urticaria, ceasing other clinical programs. Dr. Daniel Adelman has been appointed as the Acting Chief Medical Officer following the departure of Dr. Edwin Tucker.
Read more →JSPR▼ -55.1%on this newsshared move
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics reported promising results from its BEACON Phase 1b/2a study of briquilimab for chronic spontaneous urticaria, with high efficacy in single-dose cohorts. However, issues with a specific drug product lot have confounded results in some cohorts, leading to a halt in the ETESIAN asthma study. The company plans to transition affected patients to a new drug product and will enroll additional patients for further data collection.
Read more →JSPRJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria 11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12
Jasper Therapeutics announced promising results from the SPOTLIGHT study of briquilimab for chronic inducible urticaria, where 92% of participants achieved a complete response and 100% had a clinical response at the 180mg dosage. The study highlighted the rapid efficacy of briquilimab, with significant improvements noted within two weeks of treatment. Importantly, the treatment was well tolerated, with no serious adverse events reported. The company plans to discuss these findings in an upcoming conference call.
Read more →JSPR▲ +8.3%on this news
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
Jasper Therapeutics announced that four abstracts related to briquilimab will be presented at the EAACI Annual Congress 2025. The presentations will include initial clinical data from the SPOTLIGHT Phase 1b/2a study and findings on briquilimab's efficacy in treating chronic spontaneous urticaria and other mast cell-driven diseases. The congress will take place from June 13-16, 2025, in Glasgow, UK.
Read more →JSPRJasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics reported financial results for the first quarter of 2025, highlighting advancements in their lead candidate, briquilimab, a monoclonal antibody aimed at treating mast cell-driven diseases. CEO Ronald Martell noted positive data from the BEACON study on chronic spontaneous urticaria, with additional data expected by mid-year 2025. The company is also set to present further results from its CIndU and asthma studies later this year, and plans to commence a Phase 2b study by the end of 2025.
Read more →JSPR▼ -5.9%on this news
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics presented promising data on briquilimab at the AAAAI Annual Meeting, demonstrating continued safety and efficacy in addressing chronic spontaneous urticaria (CSU). The updated results from the Phase 1b/2a BEACON study indicate that briquilimab has a good safety profile with no additional adverse events linked to c-Kit blockade. There is potential for further advancement into a registrational program for CSU, with a Phase 2b study planned for late 2025. The findings reinforce briquilimab's potential as a competitive treatment option for patients experiencing CSU.
Read more →JSPRJasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
Jasper Therapeutics, a clinical-stage biotechnology company, has announced a late-breaking oral presentation for briquilimab at the upcoming 2025 AAD Annual Meeting. The presentation will share data from the Phase 1b/2a BEACON study focusing on chronic spontaneous urticaria (CSU). Briquilimab, an antibody therapy targeting c-Kit, demonstrates rapid and meaningful reductions in disease activity, highlighting its potential for treating mast cell-driven diseases. However, the company acknowledges various risks associated with the therapy's future development and market acceptance.
Read more →JSPRJasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q4 and full-year 2024, highlighting advancements in their lead drug, briquilimab, targeting mast cell-driven diseases. Positive data from clinical trials such as BEACON and SPOTLIGHT underline its potential efficacy and safety profile. Despite a reported net loss, Jasper plans to initiate a pivotal Phase 2b study in chronic spontaneous urticaria, supported by further clinical data expected mid-year. The company remains focused on its corporate strategy and clinical developments in the coming months.
Read more →JSPRJasper Therapeutics to Present at Upcoming March Investor Conferences
Jasper Therapeutics, a clinical-stage biotechnology company, has announced its participation in several upcoming investor conferences in March 2025. The conferences include the TD Cowen 45th Annual Healthcare Conference and the Barclays 27th Annual Global Healthcare Conference. Jasper is focused on the development of briquilimab, an antibody therapy targeting c-Kit for conditions such as chronic spontaneous urticaria and asthma. The company aims to leverage these conferences to enhance investor awareness and support for their clinical trials and research initiatives.
Read more →JSPRJasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics announced that they will present findings on briquilimab at the AAAAI 2025 Annual Meeting, scheduled for February 28 to March 3, 2025. The presentations include both oral and poster formats, detailing the results from the Phase 1b/2a BEACON trial for chronic spontaneous urticaria. Briquilimab targets c-Kit to treat mast cell-driven diseases, and preliminary data suggests positive clinical outcomes. This event marks a significant opportunity for Jasper to highlight their ongoing research and development efforts in this area.
Read more →JSPRJasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
Jasper Therapeutics, Inc. announced its management will present at the Oppenheimer Healthcare Life Sciences Conference on February 11-12, 2025. The company is focused on developing briquilimab, a novel antibody targeting c-Kit, for the treatment of various mast cell-driven diseases such as chronic spontaneous urticaria and asthma. Briquilimab has shown positive clinical outcomes and a good safety profile. The presentation will be available via live webcast.
Read more →JSPR▼ -60.5%on this news
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safe
Jasper Therapeutics announced positive preliminary data from its BEACON study of briquilimab, an antibody therapy for chronic spontaneous urticaria (CSU). The study showed rapid and durable symptom control, with significant reductions in UAS7 scores across multiple dosing cohorts. At the 240mg single-dose cohort, complete responses were recorded, and the safety profile was favorable. These findings support the advancement of briquilimab into a registrational program expected to begin in the second half of 2025.
Read more →JSPR▲ +8.3%on this news· ran to -63% by day 3shared move
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
Jasper Therapeutics, a clinical stage biotechnology company, will host a webinar on January 8, 2025, to present preliminary data from the BEACON study focusing on briquilimab for treating chronic spontaneous urticaria (CSU). The presentation will feature insights from management and Dr. Thomas B. Casale, the lead investigator. Briquilimab is designed to target mast cell driven diseases by inhibiting signaling through the c-Kit receptor, showing promising results in earlier studies. The company continues its clinical developments for briquilimab in CSU and other related conditions.
Read more →JSPR▲ +5.1%on this news
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
Jasper Therapeutics has announced the dosing of the first patient in its Phase 1b/2a ETESIAN clinical study, which evaluates briquilimab as a treatment for allergic asthma. This milestone marks the third clinical program for briquilimab, focusing on addressing conditions driven by mast cell activity. The ETESIAN study will investigate a single administration of briquilimab in approximately 30 patients across Canada, assessing efficacy and safety. Initial data is expected to be reported in the second half of 2025, highlighting the potential of briquilimab to provide benefit for asthma patients underserved by existing therapies.
Read more →JSPRJasper Therapeutics to Participate at Upcoming Investor Conferences
Jasper Therapeutics announced its participation in several upcoming investor conferences, including the Stifel 2024 Healthcare Conference and the Jefferies London Healthcare Conference. The company will present its novel antibody therapy, briquilimab, which targets c-Kit to address mast cell driven diseases. Briquilimab has shown positive clinical outcomes in various indications, including chronic spontaneous urticaria and asthma. Live webcasts of the presentations will be available, along with replays for 30 days following the events.
Read more →JSPRJasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its third quarter financial results, highlighting progress in its clinical programs focused on briquilimab, an antibody therapy for mast cell-driven diseases. Significant milestones were achieved, including promising initial data from the SPOTLIGHT study, where over 90% of treated patients responded positively without serious adverse events. The company has also expanded its clinical studies in chronic urticaria and asthma, securing regulatory clearances in multiple regions. Despite a continued financial loss, Jasper appears to be on a positive trajectory with its pipeline and clinical developments.
Read more →JSPRJasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Jasper Therapeutics is presenting preclinical data on briquilimab at the ACAAI Annual Scientific Meeting in Boston. The data shows briquilimab's potential to effectively deplete mast cells, which play a role in conditions like chronic spontaneous urticaria and asthma. The presentations will highlight findings from in-vitro and non-human primate studies that support the drug's mechanism of action. Jasper is currently conducting clinical studies to further evaluate briquilimab's safety and efficacy in various conditions.
Read more →JSPRJasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
Jasper Therapeutics, a clinical-stage biotechnology company, is expanding its clinical program for briquilimab, an antibody therapy for chronic spontaneous urticaria (CSU). The company announced the commencement of an open-label extension study that will enroll patients from previous studies, BEACON and SPOTLIGHT. Additionally, they received regulatory approval to add a new dosing cohort to the BEACON study, with initial data expected to be reported in January 2025. Jasper continues to work towards gathering comprehensive safety and efficacy data for its treatment.
Read more →JSPR▲ +10.5%on this news· ran to +32% by day 3
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria 14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved
Jasper Therapeutics announced promising results from the SPOTLIGHT study of briquilimab for treating chronic inducible urticaria. In the study, 14 out of 15 participants achieved a clinical response, with 83% of the 120mg cohort showing a complete response. The drug was well tolerated, exhibiting no serious adverse events. Full study results are expected to be released in the first half of 2025, and the company is looking forward to additional data from the BEACON study in early January 2025.
Read more →JSPR▲ +5.1%on this news· ran to +18% by day 3
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
Jasper Therapeutics has received clearance from Health Canada for a Clinical Trial Application to conduct a Phase 1b/2a study of briquilimab in asthma. This marks a significant step forward as the company prepares for patient enrollment and dosing, targeting a 180mg dose to assess the drug’s efficacy. The study is designed to demonstrate proof of concept for the novel antibody therapy that aims to deplete mast cells implicated in asthma. Initial trial data is anticipated in the second half of 2025.
Read more →JSPRJasper Therapeutics to Present at Present at Upcoming September Investor Conferences
Jasper Therapeutics, Inc. announced its participation in several upcoming investor conferences in September 2024, including the H.C. Wainwright Annual Global Investment Conference and the Cantor Fitzgerald Healthcare Conference. The company is focused on its investigational therapy, briquilimab, which targets mast cell driven diseases. Jasper has reported positive clinical outcomes with briquilimab, having dosed over 145 participants. Presentations at these conferences will provide an opportunity for Jasper to engage with investors and discuss the potential of its therapies.
Read more →JSPR▲ +12.4%on this news
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
Jasper Therapeutics announced its second quarter 2024 financial results, highlighting accelerated enrollment in its BEACON and SPOTLIGHT clinical studies for briquilimab, a treatment for mast cell driven diseases. The company has added an additional dosing cohort to enhance data collection and plans to present initial data from the studies later this year. Jasper reported a net loss during the quarter and has yet to analyze efficacy data. Furthermore, the company is expanding its focus to include an upcoming asthma study, demonstrating its strategic growth in mast cell-targeting therapies.
Read more →JSPR▼ -5.7%on this news
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
Jasper Therapeutics has appointed Svetlana Lucas, Ph.D., to its Board of Directors, effective June 18, 2024. Dr. Lucas brings extensive experience, having held key positions in biopharmaceutical companies and successfully leading strategic collaborations. Her expertise is expected to contribute to the development of briquilimab, a therapeutic aimed at mast cell driven diseases. This appointment follows the departure of Anna French, D. Phil., who has made significant contributions to the company.
Read more →JSPRJasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
Jasper Therapeutics, Inc. has announced its participation in the Oppenheimer Novel Targets in Immunology Summit, scheduled for June 24, 2024, in New York City. The presentation will focus on novel immunological mechanisms relevant to dermatologic disorders. The company's lead candidate, briquilimab, targets c-Kit (CD117) and aims to treat chronic spontaneous urticaria, chronic inducible urticaria, and asthma, among other conditions. Jasper has reported efficacy and safety data from over 145 participants, reinforcing its commitment to clinical development in this space.
Read more →JSPRJasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
Jasper Therapeutics recently presented preclinical data on briquilimab at the 2024 EHA Hybrid Congress. The study indicated that briquilimab effectively inhibits the SCF/c-Kit signaling pathway without causing apoptosis in healthy hematopoietic stem cells (HSCs). The findings suggest that the therapy can skew HSC differentiation, which could benefit conditions like chronic spontaneous urticaria and asthma. This aligns with the positive safety profile observed in previous clinical studies.
Read more →JSPRJasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
Jasper Therapeutics will present data on briquilimab at the EAACI Congress 2024, highlighting its potential as a treatment for mast cell driven diseases such as asthma and chronic spontaneous urticaria. Preclinical studies demonstrate that briquilimab effectively depletes mast cells, improves lung function, and has a favorable safety profile in healthy volunteers. The presentations will include details from ongoing clinical trials and showcase briquilimab's promising results in both asthma and atopic dermatitis. The Congress takes place in Valencia, Spain from May 31 to June 3, 2024.
Read more →JSPRJasper Therapeutics to Present at the Jefferies Global Healthcare Conference
Jasper Therapeutics, Inc. will present its developments on briquilimab at the Jefferies Global Healthcare Conference on June 5, 2024. The monoclonal antibody targets c-Kit to treat mast cell-driven diseases, including chronic urticaria and asthma. Briquilimab has shown efficacy and safety in more than 145 participants. A live webcast and archived replay of the presentation will be available on the company's Investor Relations website.
Read more →JSPRJasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
Jasper Therapeutics announced its first quarter 2024 financial results, highlighting ongoing studies of briquilimab for chronic urticaria. The company is seeing rapid patient enrollment in its BEACON and SPOTLIGHT trials and plans to report initial data in the later half of 2024. Additionally, Jasper is expanding briquilimab's application into asthma and has completed a successful stock offering that bolsters its financial position. The company reported a net loss of $13.7 million for the quarter.
Read more →JSPRJasper Therapeutics Announces Briquilimab Development Program in Asthma
Jasper Therapeutics has announced the initiation of a Phase 1b/2a study to evaluate briquilimab, a new monoclonal antibody targeting c-Kit, in asthma patients. The study aims to begin enrollment in Q4 2024, building on promising preclinical data demonstrating that briquilimab can deplete mast cells in the airways and mitigate allergic responses. The company is also hosting a Key Opinion Leader webinar to discuss briquilimab's potential in addressing significant unmet medical needs for asthma sufferers, particularly those unresponsive to existing therapies.
Read more →JSPRJasper Therapeutics to Present at Upcoming Investor Conferences in May
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has announced its participation in two key investor conferences in May 2024. The company will present briquilimab, a therapy targeting mast cell driven diseases, including chronic spontaneous urticaria and chronic inducible urticaria. The presentations will occur at the Capital One Securities Biotech/Biopharma Disruptors Event and the 2024 RBC Capital Markets Global Healthcare Conference. Jasper aims to leverage these events to highlight their clinical-stage developments and engage with investors.
Read more →JSPR▼ -7.4%on this news
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Jasper Therapeutics, Inc. will present briquilimab, a monoclonal antibody therapy, at the 23rd Annual Needham Virtual Healthcare Conference on April 8, 2024. The company focuses on diseases driven by mast cells, and briquilimab has shown a favorable safety and efficacy profile in clinical trials. Additionally, Jasper recently awarded stock options to new employees as part of their growth strategy. However, forward-looking statements in the press release highlight inherent risks in clinical development and market acceptance of their products.
Read more →JSPR▲ +8%on this news
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Jasper Therapeutics, Inc. announced that its management will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024. The company is known for its monoclonal antibody therapy, briquilimab, which targets mast cell diseases. With more than 145 participants treated safely, briquilimab aims to address critical health issues, although potential regulatory and clinical risks remain. A live webcast of the fireside chat will be available on Jasper's Investor Relations website.
Read more →JSPR▲ +5.6%on this news· ran to +18% by day 3shared move
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
Jasper Therapeutics has announced the first patient dosing in its Phase 1b/2a SPOTLIGHT clinical study of briquilimab for treating chronic inducible urticaria. The study aims to evaluate the safety and tolerability of briquilimab administered at two different doses to adult patients. With a goal of enrolling approximately 15 patients, preliminary data is anticipated in the second half of 2024. This research follows Jasper's previous BEACON study in chronic spontaneous urticaria, underscoring their focus on mast cell-driven diseases.
Read more →JSPRJasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
Jasper Therapeutics has reported its fiscal results for 2023, highlighting significant operational progress particularly towards briquilimab, an antibody therapy for mast cell-driven diseases. The company achieved regulatory approval for its clinical programs in chronic urticarias and completed a substantial $50 million financing. With a forward-looking approach, Jasper anticipates launching two clinical trials in 2024 and is planning to initiate another program in a mast cell-driven indication later this year. The financial report indicates a solid cash runway extending to Q3 2025, underpinning their ongoing development efforts.
Read more →JSPRJasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
Jasper Therapeutics, Inc. (JSPR) will present at the 43rd Annual TD Cowen Healthcare Conference on March 4, 2024. The company is focused on briquilimab, an antibody therapy targeting c-Kit, aimed at treating mast cell driven diseases and lower risk myelodysplastic syndromes. Briquilimab has shown promising efficacy and safety in clinical outcomes involving various conditions. A live webcast of the presentation will be available on the company's Investor Relations website, along with an archived replay.
Read more →JSPRJasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics presented promising preclinical data on briquilimab, a novel antibody therapy, at the AAAAI Annual Meeting. The studies demonstrated its efficacy in protecting against anaphylaxis and reducing mast cell populations in models of allergic asthma. The findings indicate potential for briquilimab in treating various mast cell-driven diseases, although it is still in clinical development for patients with chronic urticaria and other conditions.
Read more →JSPR▲ +18%on this news
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
Jasper Therapeutics, Inc. announced that its management will present at the Oppenheimer 34th Annual Healthcare Conference on February 13, 2024. The presentation will focus on briquilimab, a monoclonal antibody targeting c-Kit, which is in development for several mast cell and stem cell diseases. The live presentation will be accessible via the company's Investor Relations website, providing an opportunity for further engagement with stakeholders. This marks an important occasion for Jasper as it seeks to enhance awareness of its therapeutic developments.
Read more →JSPR▲ +14.5%on this news· ran to +36% by day 3shared move
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
Jasper Therapeutics has announced the pricing of an underwritten offering of 3,900,000 shares of its common stock at $12.95 per share, totaling approximately $50 million in gross proceeds. The funds from this offering will be used to support the ongoing development of briquilimab, a monoclonal antibody targeting c-Kit, and for general corporate purposes. The offering is expected to close around February 8, 2024. The transaction received participation from a mix of new and existing investors, underscoring confidence in the company's future prospects.
Read more →JSPR▲ +7.6%on this news· ran to +44% by day 3shared move
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics announced two poster presentations and an oral presentation concerning briquilimab at the AAAAI 2024 Annual Meeting. The preclinical data highlights briquilimab's efficacy against mast cell driven diseases such as chronic spontaneous and inducible urticaria. The presentations will take place from February 23-26 in Washington, D.C. The ongoing clinical studies suggest potential benefits not only in these allergic conditions but also in lower to intermediate risk myelodysplastic syndromes and stem cell transplantation preparations.
Read more →JSPRJasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jasper Therapeutics, Inc. announced inducement grants of options to purchase 12,000 shares of voting common stock to three new employees. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and indicates the company's commitment to building its team. Jasper is focused on developing briquilimab for treating diseases like chronic urticaria and myelodysplastic syndromes. While the product shows positive results in clinical trials, there are ongoing risks concerning clinical advancement and regulatory approvals.
Read more →JSPRJasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
Jasper Therapeutics has announced significant advancements for its monoclonal antibody briquilimab, including European Medicines Agency (EMA) authorization for Phase 1b/2a clinical trials targeting chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The SPOTLIGHT and BEACON studies are set to evaluate briquilimab's efficacy, with patient enrollment for SPOTLIGHT expected to start in early 2024 and initial data readouts scheduled for mid to late 2024. The company has also highlighted positive outcomes from previous trials with briquilimab, setting a forward-looking path for its development in various mast cell-driven diseases.
Read more →JSPR▼ -13.7%on this newsshared move
Jasper Therapeutics, Inc. Announces Reverse Stock Split
Jasper Therapeutics, Inc. has announced a reverse stock split of 1-for-10 effective January 4, 2024. This decision, approved by stockholders, aims to help the company regain compliance with Nasdaq's minimum bid price requirement. Following the split, the total number of shares will be reduced significantly from approximately 111.6 million to approximately 11.2 million. Jasper is currently developing briquilimab for various conditions including chronic spontaneous urticaria and myelodysplastic syndromes.
Read more →JSPRJasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
Jasper Therapeutics announced positive final results from its Phase 1 study of briquilimab, focusing on patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing hematopoietic cell transplant. The results indicated successful engraftment and a favorable safety profile compared to standard treatment options. The findings were presented by Dr. Arpita Gandhi at the ASH 2023 Annual Meeting. Jasper is also developing briquilimab for other indications, including Fanconi Anemia, and plans further clinical trials.
Read more →JSPRJasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
Jasper Therapeutics has announced the dosing of the first patient in its Phase 1b/2a clinical trial of briquilimab for chronic spontaneous urticaria (CSU). The BEACON study aims to assess the safety, tolerability, and pharmacokinetics of briquilimab in patients who are refractory to the existing treatment, omalizumab. Approximately 40 patients will be enrolled in the study, with preliminary data anticipated in mid-2024. Jasper sees this milestone as a testament to the effectiveness of their clinical team and a significant step forward in developing therapies for mast cell diseases.
Read more →JSPR▼ -8.1%on this news· ran to -21% by day 3
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Jasper Therapeutics, Inc. reported its third quarter 2023 financial results, highlighting FDA clearance for its investigational new drug application for briquilimab aimed at treating mast cell driven diseases. The company emphasized a robust balance sheet and productive leadership additions, positioning itself well for future clinical studies. However, Jasper reported a net loss of $17.5 million for the quarter, with operating expenses having risen compared to the previous year.
Read more →JSPRJasper Therapeutics to Participate at Upcoming Medical and Investor Conferences
Jasper Therapeutics, Inc. is set to participate in several upcoming medical and investor conferences throughout November 2023. Notably, they will present briquilimab, an anti-CD117 antibody, at the ACAAI Annual Scientific Meeting and other healthcare conferences, highlighting its therapeutic potential for mast cell-related diseases and myelodysplastic syndromes. Briquilimab has shown safety and efficacy in over 145 participants, suggesting promise in its clinical applications. Live webcasts of these presentations will be available for investors and interested parties.
Read more →JSPRJasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023
Jasper Therapeutics announced positive final results from a Phase 1 study of briquilimab, presented at the ASH 2023 Annual Meeting. The study indicates that briquilimab combined with fludarabine and low-dose irradiation leads to successful engraftment without the toxicities generally associated with busulfan regimens. The findings support the safety profile of briquilimab and highlight its clinical potential in treating acute myeloid leukemia and myelodysplastic syndromes. Future studies will also explore briquilimab's efficacy against mast cell diseases.
Read more →JSPRJasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors
Jasper Therapeutics has appointed Thomas G. Wiggans as the new Chairperson of its Board of Directors, effective immediately. He replaces Bill Lis, who will retire from the Board in December. Wiggans brings over four decades of experience in the biopharmaceutical industry, particularly in dermatology, and joins the company at a pivotal time as it launches its clinical study of briquilimab. Both current CEO Ronald Martell and outgoing Chair Lis expressed confidence in Wiggans's leadership amidst Jasper's ongoing development of cancer therapies and mast cell-driven diseases.
Read more →JSPRBriquilimab is an investigative drug and is not approved for any indication Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this "Presentat
Jasper Therapeutics presented an investor update highlighting briquilimab, an investigative drug targeting mast cell-mediated diseases, including Chronic Spontaneous Urticaria and Chronic Inducible Urticaria. While the drug shows promise for effective mast cell depletion with a favorable safety profile, it is not yet approved for any indication. The company plans to provide updates from several clinical studies in 2024, though the future of briquilimab remains uncertain due to the inherent risks and uncertainties in drug development.
Read more →JSPR▲ +16.3%on this newsshared move
Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023
Jasper Therapeutics is hosting a Key Opinion Leader (KOL) webinar on October 11, 2023, to explore the potential of briquilimab as a treatment for chronic urticaria. The event will feature prominent experts who will discuss the current treatment landscape and the distinct mechanism of action of briquilimab, which targets the c-Kit receptor. Jasper aims to initiate clinical studies to assess briquilimab's efficacy and optimal dosing for chronic spontaneous urticaria and chronic inducible urticaria. The company's prior studies indicate a favorable safety and efficacy profile for briquilimab in various related conditions.
Read more →JSPR▲ +16.3%on this newsshared move
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical
Jasper Therapeutics has announced the FDA clearance of its IND application for a Phase 1b/2a clinical study evaluating subcutaneous briquilimab in chronic spontaneous urticaria patients. The trial, expected to begin dosing by the end of 2023, aims to address the needs of patients who are refractory to existing treatments like omalizumab. Early data from the study is anticipated by mid-2024, suggesting a promising advancement in the treatment of mast cell driven diseases. Additionally, preparations are underway for a proof of concept study in chronic inducible urticaria, expected to start in early 2024.
Read more →JSPR▼ -9%on this news
Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer Jeet Mahal Continues as
Jasper Therapeutics, a biotechnology company, has appointed Herb Cross as its new Chief Financial Officer, enhancing its leadership team as it prepares for growth. Jeet Mahal will continue to serve as Chief Operating Officer, allowing him to focus on operational needs. The company is advancing clinical studies for briquilimab, a novel antibody therapy aimed at treating chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes, and conditioning for stem cell transplants. Cross brings over two decades of financial experience in the biotech sector, further strengthening Jasper's strategic position.
Read more →JSPRJasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium All three Fanconi Anemia patients treated with br
Jasper Therapeutics announced new positive Phase 1b data regarding briquilimab as a conditioning agent for patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium. The ongoing clinical trial demonstrated encouraging results, with all three treated patients achieving full blood count recovery. Furthermore, the treatment was well-tolerated, eliminating the need for traditional chemotherapy and irradiation. The outcomes suggest that briquilimab could significantly enhance treatment outcomes for Fanconi Anemia patients.
Read more →JSPR▲ +11%on this news
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference
Jasper Therapeutics, a clinical-stage biotechnology company, announced its participation in the Cantor Fitzgerald 2023 Global Healthcare Conference set for September 26-28, 2023. CEO Ronald Martell will present on September 27th, providing insights into the company’s development of briquilimab, a monoclonal antibody targeting c-Kit for chronic diseases. The company has reported a positive safety and efficacy profile for briquilimab across various diseases, including lower to intermediate risk myelodysplastic syndromes.
Read more →JSPRJasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome Strengthened the Board of Direct
Jasper Therapeutics, Inc. has announced its financial results for the second quarter of 2023, showcasing a continued focus on the development of briquilimab, a novel therapy targeting c-Kit for various conditions. The company has successfully dosed the first patient in a Phase 1 trial for lower-risk myelodysplastic syndrome and plans to start a study for chronic spontaneous urticaria soon. Despite a net loss of $16.08 million, Jasper maintains a solid cash position, positioning itself for future growth in the biotechnology sector.
Read more →JSPRJasper Therapeutics Strengthens Management Team with Key Appointments
Jasper Therapeutics has appointed Patricia Carlos as Senior Vice President of Regulatory Affairs and Quality and Annette Marcantonio as Vice President of Clinical Operations. These appointments come as the company is advancing its product briquilimab, aimed at treating conditions such as chronic spontaneous urticaria and myelodysplastic syndromes. Both executives bring extensive experience in drug development and regulatory processes, expected to enhance Jasper's capabilities in clinical and operational aspects. This strategic move is aligned with Jasper's goal to strengthen its leadership ahead of upcoming clinical studies.
Read more →JSPRJasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome
Jasper Therapeutics has announced that the first patient has been dosed in a Phase 1 trial of briquilimab, aimed at treating lower-risk myelodysplastic syndrome (LR-MDS). This trial marks a significant milestone in the development of briquilimab, which targets c-Kit (CD117) and is intended as a second-line therapy. Conducted at Moffitt Cancer Center, the trial will evaluate the safety and tolerability of briquilimab, enrolling up to 30 patients. The company aims to address the limited treatment options for LR-MDS and improve patient outcomes and quality of life.
Read more →JSPRJasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appoin
Jasper Therapeutics has appointed Scott Brun, M.D., to its Board of Directors, where he will also serve as Chairperson of the Research and Development Committee. His extensive background in drug development, particularly in immunology, is expected to benefit the company's strategy for briquilimab, a novel antibody therapy targeting c-Kit. Concurrently, another board member, Vishal Kapoor, was appointed to the Audit and Compensation Committees. This organizational change aims to strengthen the executive team's capabilities as they advance their clinical programs.
Read more →JSPR▲ +6.2%on this news
Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer
Jasper Therapeutics has appointed Dr. Edwin J. Tucker as Chief Medical Officer to lead the clinical development of briquilimab, a monoclonal antibody targeting c-Kit. The appointment coincides with the company’s expansion of briquilimab's clinical program to address diseases such as chronic spontaneous urticaria and myelodysplastic syndromes. Dr. Daniel Adelman, previously serving as Acting Chief Medical Officer, will now join the Scientific Advisory Board as a Senior Clinical Advisor.
Read more →JSPRHarnessing the Power of Jasper's Differentiated c - Kit Therapeutic Approach Nasdaq: JSPR June 2023 Safe Harbor Statements Briquilimab is an investigative drug and is not approved for any indication 2 Forward - Looking S
Jasper Therapeutics has presented its investigational drug Briquilimab, which targets c-Kit, for various mast and stem cell diseases. The drug has shown promising potential for chronic spontaneous urticaria, with initial clinical data expected by late 2023. Future expansion into areas such as allergic asthma and eosinophilic esophagitis is planned. The company highlighted Briquilimab's favorable drug properties and its potential role in enhancing transplant efficacy by depleting unhealthy stem cells.
Read more →JSPR▲ +5.4%on this news
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous Urticaria Presented Positive Follow-up Clinica
Jasper Therapeutics, Inc. has reported its financial results for the first quarter of 2023, highlighting strategic business updates including the expansion of briquilimab's development into chronic spontaneous urticaria. During this period, the company secured significant capital and presented promising research data at major conferences. Despite a considerable increase in net loss to $14,260 and rising operating expenses, Jasper remains optimistic about briquilimab's potential applications in treating various conditions.
Read more →JSPRJasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board
Jasper Therapeutics, Inc. has appointed Dr. Stephen J. Galli to its Scientific Advisory Board, a move expected to bolster the company's expertise in developing briquilimab, a monoclonal antibody targeting c-Kit for chronic spontaneous urticaria and myelodysplastic syndromes. Dr. Galli, a leading figure in immunology with extensive research experience, will contribute valuable insights to the company's research efforts. The appointment comes at a time when Jasper is advancing its clinical programs for briquilimab, which has shown efficacy and safety in prior studies. This strategic addition to the advisory board aims to enhance Jasper's capabilities in therapeutic development.
Read more →JSPRJasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources
Jasper Therapeutics has appointed Matthew Ford as the new Vice President of Human Resources. Ford brings extensive experience from previous roles at Tricida and Jazz Pharmaceuticals, where he successfully built high-performing teams. His appointment is seen as a strategic move to support the company's development of briquilimab, a monoclonal antibody aimed at treating various diseases. The company maintains a solid focus on advancing briquilimab's clinical development and positioning in the market.
Read more →JSPRJasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations
Jasper Therapeutics has appointed David Hinds as Senior Vice President of Development Operations. Hinds, with over 25 years of experience, is expected to drive the company's clinical research and operations, especially in the advancement of briquilimab. This monoclonal antibody targets c-Kit (CD117) to treat chronic spontaneous urticaria and myelodysplastic syndromes, among other conditions. The company is currently reinforcing its efforts in clinical trials and enhancing its approaches to stem cell transplants.
Read more →JSPRJasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium
Jasper Therapeutics, Inc. announced its participation in the Cantor Fitzgerald's 'The Future of Oncology Virtual Symposium' scheduled for April 3-5, 2023. Dr. Wendy Pang, the Senior VP of Research and Translational Medicine, will present a panel on innovative solutions for hematological malignancies. The company is focused on briquilimab, a monoclonal antibody therapy targeting c-Kit, which has shown promise in treating various blood and stem cell disorders.
Read more →JSPRJasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
Jasper Therapeutics has appointed Dr. Daniel Adelman as its Acting Chief Medical Officer, leveraging his extensive experience in developing therapies for immunologic diseases. Adelman's track record includes leadership roles at prominent biopharma companies, enhancing Jasper's capability in advancing its pipeline, particularly with briquilimab. The company aims to address conditions like chronic spontaneous urticaria and myelodysplastic syndromes. Adelman's expertise positions Jasper favorably in the competitive landscape of immune-based therapeutics.
Read more →JSPR▼ -7%on this news
Jasper Therapeutics to Present at Upcoming Conferences
Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology firm focused on novel antibody therapies, has announced participation in two upcoming virtual conferences. Ronald Martell, the company's CEO, will discuss new therapies for chronic spontaneous urticaria on March 13 and present a corporate overview at the Oppenheimer Conference. Additionally, Jasper is advancing its lead candidate, briquilimab, targeting serious conditions like myelodysplastic syndromes and various rare diseases. The company emphasizes its innovative approaches while acknowledging the risks in development and market acceptance.
Read more →JSPRJasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update Announced Expansion of Briquilimab (formerly known as JSP191) Development Strategy to Include Chronic Spontaneous Urticaria Present
Jasper Therapeutics reported its fiscal 2022 financial results and announced an expanded development strategy for briquilimab, which now includes chronic spontaneous urticaria. The company highlighted the transformational period it has experienced, characterized by successful capital raises and advancements in clinical trials for a variety of conditions. Significant data supporting briquilimab's efficacy was presented at leading medical meetings, establishing a strong rationale for further development. Jasper is positioning itself to initiate clinical trials, demonstrating confidence in briquilimab's potential impact on patients with chronic and rare diseases.
Read more →JSPRJasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR Oral Presentation, Abstract #
Jasper Therapeutics, Inc. has announced positive Phase 1 data for its c-Kit targeting antibody, briquilimab, presented at the 2023 Transplantation & Cellular Therapy Meetings. The study demonstrated that briquilimab, in combination with fludarabine and low-dose irradiation, resulted in successful engraftment and a favorable safety profile among older adults with acute myeloid leukemia or myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. The findings support further development of briquilimab as a potentially safe and effective conditioning agent for stem cell transplants.
Read more →JSPRJasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors
Jasper Therapeutics has appointed Vishal Kapoor to its Board of Directors. Kapoor, with a strong background in the healthcare industry, is expected to provide strategic guidance as Jasper advances its development programs for briquilimab, intended for treating various chronic diseases. The company highlighted its successful public offering and confidence in achieving clinical milestones with its novel antibody therapies targeting c-Kit.
Read more →JSPRJasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients Data Presented in Plenary Session at the 2023 Transplantation &
Jasper Therapeutics has presented positive follow-up clinical data from an investigator-sponsored study of briquilimab as a conditioning agent for sickle cell disease (SCD). The data revealed that all evaluated patients achieved donor myeloid chimerism of 100%, indicating successful engraftment. Additionally, there were no observed severe adverse events related to briquilimab. This study, presented at the 2023 Transplantation & Cellular Therapy Meetings, aims to improve curative therapies for SCD and beta-thalassemia through advanced antibody-based conditioning methods.
Read more →JSPR▲ +8.4%on this news
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jasper Therapeutics, Inc. announced the grant of a True-Up Option to its President and CEO, Ronald Martell, allowing him to purchase 1,093,831 shares of common stock as part of an equity incentive plan. This grant followed the company's successful public offering, which raised approximately $103.5 million. The True-Up Option has a set exercise price and vests over four years, contingent upon Mr. Martell's continued employment. This move aligns Martell's interests with those of shareholders as Jasper continues to develop its lead therapy, briquilimab, for various severe conditions.
Read more →JSPRJasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023
Jasper Therapeutics, a biotechnology firm, will host an investor conference call on January 31, 2023, to discuss corporate updates. The call will feature the management team and will be accessible via telephone or a live webcast. The focus will be on their monoclonal antibody, briquilimab, which is aimed at treating chronic diseases and is advancing through clinical trials with a positive safety profile.
Read more →JSPRJasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Jasper Therapeutics has successfully closed its underwritten public offering of 69 million shares of common stock at $1.50 each, resulting in gross proceeds of approximately $103.5 million. The offering included the full exercise of the underwriters' option to purchase 9 million additional shares, reflecting strong market interest. The company is focused on developing briquilimab, a monoclonal antibody aimed at treating various chronic mast and stem cell diseases, with promising clinical data reported from over 130 subjects. The company plans to use proceeds to further its ongoing clinical trials and potential applications of its therapies.
Read more →JSPR▲ +9.5%on this newsshared move
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
Jasper Therapeutics has announced the pricing of a public offering of 60 million shares of its common stock at a price of $1.50 per share, aiming to raise approximately $90 million in gross proceeds. The funds will be used for various corporate purposes, including capital expenditures and working capital. The offering is managed by Credit Suisse and William Blair, with a closing expected around January 27, 2023. Additionally, investors may exercise an option to purchase more shares, subject to conditions.
Read more →JSPR▼ -5.6%on this newsshared move
Jasper Therapeutics Announces Proposed Public Offering of Common Stock
Jasper Therapeutics has announced its intentions to conduct an underwritten public offering of common stock, subject to market conditions. The biotechnology company aims to use the proceeds to advance its offerings, including briquilimab, a monoclonal antibody targeting c-Kit for treating certain diseases. Underwriters have been appointed to manage this offering, but there is inherent uncertainty regarding completion and terms. This move shows Jasper's commitment to enhancing its clinical development efforts amid fluctuating market conditions.
Read more →JSPR▲ +7.9%on this news
Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Three abstracts highlight the safety and efficacy o
Jasper Therapeutics announced positive data regarding its drug briquilimab, which will be presented at the 2023 Tandem Meetings. The data includes results from a Phase 1 study where briquilimab, combined with low-toxicity radiation, achieved successful donor engraftment and remission in older AML patients. Among the 12 treated patients, 8 achieved durable remissions and showed promising outcomes with reduced rates of graft-versus-host disease. The findings suggest briquilimab’s potential to improve safety and efficacy in stem cell transplants.
Read more →JSPRJasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases
Jasper Therapeutics has announced the prioritization of briquilimab, its lead product candidate, focusing on chronic diseases such as urticaria and lower-risk MDS, as well as stem cell transplants for sickle cell disease. The development will include a new clinical study in severe chronic urticaria and continued studies for other rare diseases. Jasper is optimistic about briquilimab's potential based on existing preclinical and clinical data that suggests promising efficacy and safety. The company aims to secure pathways for a pivotal Phase 3 study while continuing recruitment for ongoing studies.
Read more →JSPR▼ -21.9%on this news· ran to -42% by day 3
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant
Jasper Therapeutics has received orphan drug designation from the European Medicines Agency for briquilimab, a monoclonal antibody intended for use in conditioning treatment prior to hematopoietic stem cell transplants. This designation follows a similar approval from the FDA, highlighting the therapy's potential to address the toxicities associated with traditional conditioning methods. Clinical studies have shown that briquilimab has been well tolerated, with promising safety and efficacy results observed in patients with severe combined immunodeficiency and acute myeloid leukemia. The company remains committed to advancing briquilimab globally.
Read more →JSPR▲ +467.4%on this newsshared move
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Jasper Therapeutics announced encouraging results from a Phase I/II clinical trial of briquilimab for patients with sickle cell disease and beta thalassemia. In the trial, all three participants achieved successful engraftment of donor stem cells, with no observed severe adverse events related to the treatment. The first participant's hemoglobin levels increased significantly from baseline, demonstrating briquilimab's potential as a conditioning agent. These results are particularly promising for high-risk patients who may not benefit from traditional transplant methods.
Read more →JSPRJasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 1
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update REDWOOD CITY, Calif., November 10, 2022 - Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and
Read more →JSPRJasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting
REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data from the company’s investigator-sponsored study of JSP191 as a conditioning age
Read more →JSPRJasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant
JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS), SCID, Fanconi anemia and Sickle Cell Disease On track to initiate a new study of
Read more →JSPRJasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update - First patient dosed in a sponsored trial of JSP191 conditioning in patients with Fanconi Anemia - On schedule to initiat
Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update CITY, Calif., August 12, 2022 - Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine,
Read more →JSPR▲ +17.3%on this news· ran to +35% by day 1
Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will participate at the LifeSci Partners 2nd Annual Genetic Medicines Sym
Read more →JSPR▼ -5.7%on this news
Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference
REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company is participating in the William Blair 42nd Annual Growth Stock Conference
Read more →JSPRJasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022
REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 1
Read more →JSPRJasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the dosing of the first patient in the Company’s sponsored research of the Center for Defin
Read more →JSPRJasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update - Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023 - Clini
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update REDWOOD CITY, Calif., May 12, 2022 - Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a biotechnology company focused on hematopoietic stem cell therapies, today announced fir
Read more →JSPRJasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc., (NASDAQ: JSPR) a biotechnology company focused on hematopoietic stem cell therapies, today announced that after discussion with the FDA the company plans to initiate a registrational study of JSP1
Read more →JSPRJasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
JSP191 is well tolerated with no treatment-related severe adverse events in 24 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study 24 of 24 patients achieved successful engraftment with neutrophil recovery 20 of 24 patients
Read more →JSPRJasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies
REDWOOD CITY, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that it will host an in-person key opinion leader (KOL) webinar on transforming the field
Read more →JSPR▲ +6%on this news
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting
REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that updated data from the Company’s ongoing study of JSP191 as single agent conditioning
Read more →JSPRJasper Therapeutics Announces Management Changes to Strengthen Leadership Team
Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team REDWOOD CITY, Calif., March 21, 2022 - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced changes to its managemen
Read more →JSPRJasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update
Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update CITY, Calif., March 18, 2022 - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for
Read more →JSPRTransforming the Field of Hematopoietic Stem Cell Therapies Nasdaq: JSPR March 2022 2 JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement Forward - Looking Statements This investo
Transforming the Field of Hematopoietic Stem Cell Therapies Nasdaq: JSPR March 2022 2 JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement Forward - Looking Statements This investor presentation and any accompanying oral presentation (toge
Read more →JSPR▼ -8%on this news
Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
REDWOOD CITY, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conf
Read more →JSPRJasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer - William Lis to Continue as Chairman, Board of Directors --- REDWOOD CITY, CA
Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer Continue as Chairman, Board of Directors --- REDWOOD CITY, CA; February 28, 2022 - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant
Read more →JSPRJasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR JSP191 is well tolerated with no treatment-related
Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR REDWOOD CITY, CA; February 24, 2022 - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on
Read more →JSPR▲ +6%on this news· ran to +25% by day 1
Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting
JSP191 is well tolerated with no treatment-related adverse events in dose-escalation study Single-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical benefit REDWOOD CITY, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeuti
Read more →JSPRJasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update REDWOOD CITY, Calif., November 12, 2021 - Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced resu
Read more →JSPRJasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy
REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AV
Read more →JSPRJasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit
Read more →JSPRJasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy company expected to begin trading on the Nasdaq Global Select Market under "JS
Read more →JSPRAmplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc. REDWOOD CITY, Calif., &
Healthcare Acquisition Corporation Announces Shareholder Approval Business Combination with Jasper Therapeutics, Inc. CITY, Calif., & NEW YORK - September 22, 2021 - Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHC) ("AMHC"), a special purpose acquisition company, to
Read more →JSPRJasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members REDWOOD CITY, Calif., and New York
Therapeutics and Amplitude Healthcare Acquisition Corporation Announce REDWOOD CITY, Calif., and New York - September 20, 2021, Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporatio
Read more →JSPREnabling Cures with Hematopoietic Stem Cell Transplants September 2021 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement 2 About this Presentation
Enabling Cures with Hematopoietic Stem Cell Transplants September 2021 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement 2 About this Presentation This investor presentation (this "Presentation") is for in
Read more →JSPRPresentation Transcript Bill Lis (Executive Chairman and Chief Executive Officer of Jasper Therapeutics, Inc.): Hello and thank you for joining today's webcast. My name is Bill Lis, I'm the executive chairman and CEO of
Presentation Transcript Lis (Executive Chairman and Chief Executive Officer of Jasper Therapeutics, Inc.): and thank you for joining today's webcast. My name is Bill Lis, I'm the executive chairman and CEO of Jasper. We are really pleased today to announce the proposed merger
Read more →JSPRJasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation Transaction includes up to $100 mi
Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation includes up to $100 million in trust at Amplitude and a concurrent, fully committed $100 mil
Read more →JSPRAmplitude Healthcare Acquisition Corporation Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing
Healthcare Acquisition Corporation Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing January York, NY, Jan. 07, 2020 (GLOBE NEWSWIRE) - Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHCU) (the "Company") announced today that, commencin
Read more →JSPRINDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of November 22, 2019 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC To the Stockholders and the Board of Directors Amplitude Heal
Read more →JSPRAmplitude Healthcare Acquisition Corporation Announces Pricing of $100,000,000 Initial Public Offering New York, NY
Healthcare Acquisition Corporation Announces Pricing of $100,000,000 Initial Public Offering York, NY, Nov. 19, 2019 (GLOBE NEWSWIRE) - Amplitude Healthcare Acquisition Corporation (the "Company") announced today that it priced its initial public offering of 10,000,000 units at
Read more →Competitive Position
How JSPR ranks across every disease it competes inCompetitive Position is a premium feature
See how JSPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial